Sign in Subscribe

chemo

A collection of 72 issues

Adding immunotherapy to chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Adding immunotherapy to chemotherapy before surgery in stage III colon cancer — Clinical Colorectal Cancer The AZUR-4 trial is a Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in previously untreated T4N0 or stage III mismatch repair proficient/

CRC Research Finding

Skip to content The CRC Digest ▸ Meta-Analysis Compares TAS-102 and Regorafenib Sequencing in Later-Line mCRC A systematic review and meta-analysis compared efficacy and safety of TAS-102 followed by regorafenib versus the reverse sequence in patients with metastatic colorectal cancer who had previously failed chemotherapy. (Chin Clin Oncol) This content is

BREAKWATER explores molecular markers in BRAF V600E disease

Skip to content The CRC Digest BREAKWATER explores molecular markers in BRAF V600E disease Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team.

KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab

Skip to content The CRC Digest KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab A 57-year-old man with KRAS G13D-mutant metastatic rectal cancer and fluoropyrimidine intolerance achieved approximately 16.6 months of disease control with trifluridine/tipiracil plus bevacizumab integrated with liver-directed treatments,

BRAF V600E triplet regimen advances in phase 3 trial

Skip to content The CRC Digest BRAF V600E triplet regimen advances in phase 3 trial BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology) This content

ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases

Skip to content The CRC Digest ◆ TRIAL DATA ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.

Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS

RAS/BRAF wild-type patients: Maintenance strategies compared

Skip to content The CRC Digest RAS/BRAF wild-type patients: Maintenance strategies compared Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute) This content is informational only and does not constitute medical advice. Always

CRC Research Finding

Skip to content The CRC Digest ◇ GDF15 Protein Linked to Chemotherapy Resistance in Colorectal Cancer Lab studies identified GDF15 as a key molecule driving resistance to 5-fluorouracil and oxaliplatin by promoting stem cell-like properties in colorectal cancer cells; high GDF15 expression in liver metastasis specimens was associated with early recurrence

CRC Research Finding

Skip to content The CRC Digest ◆ Sequential vs. Upfront Oxaliplatin in Metastatic Colorectal Cancer: Long-Term Results (Communications Medicine) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com